Download PDF
Hamostaseologie 1984; 04(04): 105-110
DOI: 10.1055/s-0038-1659932
Originaler Artikel
Schattauer GmbH

Gerinnungsstörungen und thromboembolische Komplikationen bei Patienten mit nephrotischem Syndrom

F. Llach
1   Department of Medicine, University of Oklahoma, Health Science Center, and Veterans Administration Medical Center, Oklahoma City, Oklahoma
› Author Affiliations
Further Information

Publication History

Publication Date:
22 June 2018 (online)

Also available at
    Permissions and Reprints

 

 

  • Literatur

  • 1 Rayer P.F.O. Traite des Maladies des Reins et des Alterations de la Secretions Urinaire. Vol. 2. Paris, Bailliere, Paris: 1840: 590-599.
    PubMedGoogle Scholar
  • 2 Derrow H.A, Schlesinger M.J, Savitz H.A. Chronic progressive occlusion of the inferior vena cava and the renal and portal veins with the clinical picture of the nephrotic syndrome. Report of a case with a review of the literature. Arch. Int. Med. 63: 626-647 1939;
    CrossrefPubMedGoogle Scholar
  • 3 Harrison C.V, Milne M.D, Steiner R.E. Clinical aspects of renal vein thrombosis. Quart. J. Med. 25: 285-298 1956;
    PubMedGoogle Scholar
  • 4 Hasson J, Berkman J.I, Parker J.G, Rifkin H. A clinical pathological study of chronic renal vein thrombosis in adults. Ann. Int. Med. 47: 493-517 1957;
    CrossrefPubMedGoogle Scholar
  • 5 Bennet W.M. Renal vein thrombosis and nephrotic syndrome. Ann. Int. Med. 83: 577-578 1975;
    CrossrefPubMedGoogle Scholar
  • 6 Pohl M.A, MacLaurin J.P, Alfidi R.J. Renal vein thrombosis and the nephrotic syndrome. 10th Annual Meeting of the American Society of Nephrology, Book of Abstract 10:20A, Washington DC, 1977.
    PubMedGoogle Scholar
  • 7 Trew P, Biava C, Jacobs R, Hopper J. Renal vein thrombosis in membranous glo-merulonephropathy: incidence and association. Medicine 57: 69-82 1978;
    CrossrefPubMedGoogle Scholar
  • 8 Noel L.H, Zanetti M, Droz D. et al. Long-term prognosis of idiopathic membranous glomerulonephritis. Amer. J. Med. 66: 82-90 1979;
    CrossrefPubMedGoogle Scholar
  • 9 Winter S.C, Wagoner R.D, Bowie E.J.W. et al. Dysfibrinogenemia and hypercoagulability in patients with membranous nephropathy. Thromb. Hemost. 42: 67 1979;
    PubMedGoogle Scholar
  • 10 Andrassy K, Ritz E, Bommer J. Hypercoagulability in the nephrotic syndrome. Klin. Wschr. 58: 1029-1036 1980;
    CrossrefPubMedGoogle Scholar
  • 11 Monteon E, Trevino A, Exaire E. et al. Nephrotic syndrome with renal vein thrombosis treated with thrombectomy and anticoagulants. 8th International Congress of Nephrology, Book of Abstracts, p. 82, Athens, Greece 1981.
    PubMedGoogle Scholar
  • 12 Llach F, Papper S, Massry S.G. The clinical spectrum of renal vein thrombosis: Acute and chronic. Amer. J. Med. 69: 819-827 1981;
    PubMedGoogle Scholar
  • 13 Kanfer A, Kleinknetch D, Broyer M. et al. Coagulation studies in 45 cases of nephrotic syndrome without uremia. Thromb. Diathes. Haemorrh. 24: 562-571 1970;
    PubMedGoogle Scholar
  • 14 Kendall A.G, Lohmann R.E, Dossetor J.B. et al. Nephrotic syndrome: A hypercoagulable state. Arch. Int. Med. 127: 1021-1027 1971;
    CrossrefPubMedGoogle Scholar
  • 15 Kauffman R, Veltkamp J, Tilberg N, Van Es L. Acquired antithrombin III deficiency and thrombosis in the nephrotic syndrome. Amer. J. Med. 65: 607-613 1978;
    CrossrefPubMedGoogle Scholar
  • 16 Kuhlmann U, Stevrer J, Rhyner K. et al. Platelet aggregation and B-thromboglobulin levels in nephrotic patients with and without thrombosis. Clin. Nephrol. 75: 229-235 1981;
    PubMedGoogle Scholar
  • 17 Handley D.A, Lawrence J.R. Factor IX deficiency in the nephrotic syndrome. Lancet I: 1079-1081 1967;
    PubMedGoogle Scholar
  • 18 Natelson E.A, Lynch E.C, Hettig R.A. et al. Acquired Factor IX deficiency in the nephrotic syndrome. Ann. Int. Med. 73: 373-378 1970;
    CrossrefPubMedGoogle Scholar
  • 19 Lange III L.G, Carvalho A, Bagdasarian A. et al. Activation of Hageman Factor in the nephrotic syndrome. Amer. J. Med. 56: 565-568 1974;
    CrossrefPubMedGoogle Scholar
  • 20 Green D, Arruda J, Honig G. et al. Urinary loss of clotting factor due to hereditary membranous nephropathy. Amer. J. clin. Path. 65: 376-383 1976;
    PubMedGoogle Scholar
  • 21 Thompson C, Forbes C.D, Prentice C.R.M. et al. Changes in blood coagulation and fibrinolysis in the nephrotic syndrome. Quart. J. Med. 43: 399-407 1974;
    PubMedGoogle Scholar
  • 22 Earley L.E, Haule R.J, Hopper J. et al. Nephrotic syndrome. Calif. Med. 775: 12-41 1971;
    PubMedGoogle Scholar
  • 23 Takeda Y, Chen A. Fibrinogen metabolism and distribution in patients with the nephrotic syndrome. J. Lab. clin. Med. 70: 678-685 1967;
    PubMedGoogle Scholar
  • 24 Clarkson A, McDonald M, Petrie J, Cash H, Robson J. Serum and urinary fibrinogen/fibrin degradation products in glomerulonephritis. Brit. Med. J. 3: 447-451 1971;
    CrossrefPubMedGoogle Scholar
  • 25 Cade R, Spooner G, Juncos L. et al. Chronic renal vein thrombosis. Amer. J. Med. 63: 387-396 1977;
    CrossrefPubMedGoogle Scholar
  • 26 Hall C, Pejhan N, Terry J, Blainey J. Urinary fibrin/fibrinogen degradation products in nephrotic syndrome. Brit. Med. J. 1: 419-422 1975;
    CrossrefPubMedGoogle Scholar
  • 27 Sixma J.J. Techniques for diagnosis pre-thrombotic states. A review. Thrombos. Haemostas. 40: 252-259 1978;
    PubMedGoogle Scholar
  • 28 Yin E.T, Wessler S, Stroll P.J. Identity of plasma-activated factor X inhibitor with antithrombin III and heparin cofactor. J. Biol. Chem. 246: 3712-3715 1971;
    PubMedGoogle Scholar
  • 29 Rosenberg J.S, McKenna P, Rosenberg R.D. The inhibition of human factor IXa by human antithrombin-heparin cofactor. J. Biol. Chem. 250: 8883-8888 1975;
    PubMedGoogle Scholar
  • 30 Rosenberg R.D. Actions and interactions of antithrombin and heparin. New Engl. J. Med. 292: 146-149 1975;
    CrossrefPubMedGoogle Scholar
  • 31 Godai H.C, Rygh M, Laake K. Progressive inactivation of purified factor VII by heparin and antithrombin III. Thromb. Res. 5: 773-776 1974;
    CrossrefPubMedGoogle Scholar
  • 32 Harpel P.C, Rosenberg R.D. Macroglo-bulin and antithrombin heparin cofactor: Modulators of haemostatic and inflammatory reactions. In: Spaet T.H. (Ed.) Progress in Hemostasis and Thrombosis. Grune and Stratton; New York: 1976. Vol. 3 145-189.
    Google Scholar
  • 33 Arneson H, Fagerhol M.K. Macroglobulin, antitrypsin, and antithrombin III in plasma and serum during fibrinolytic therapy with urokinase. Scand. J. Clin. Lab. Invest. 29: 259-265 1972;
    CrossrefPubMedGoogle Scholar
  • 34 Egebert O. Inherited antithrombin deficiency causing thrombophilia. Thrombos. Diathes. haemorrh. 13: 516-530 1965;
    PubMedGoogle Scholar
  • 35 Marciniak E, Farley C.H, DeSimone P.A. Familial thrombosis due to antithrombin III deficiency. Blood 43: 219-231 1974;
    PubMedGoogle Scholar
  • 36 Thaler E, Lechner K. Thrombophilie bei erworbenem Antithrombin III-Mangel von Patienten mit nephrotischem Syndrom. In: Marx R, Thiess H. (Hrsg.) Niere, Blutgerinnung und Hämostase. Schattauer; Stuttgart: 1978. S.123-129.
    Google Scholar
  • 37 Hedner U, Nilsson I.M. Antithrombin III in a clinical material. Thromb. Res. 3: 631-636 1973;
    CrossrefPubMedGoogle Scholar
  • 38 Thaler E, Blazar E, Kopsa H, Ping-gera W. Acquired antithrombin III deficiency in patients with glomerular proteinuria. Hemostasis 7: 257-272 1978;
    PubMedGoogle Scholar
  • 39 Astedt B, Isacson S, Musson I.M. et al. Thrombosis and oral contraceptives: Possible predisposition. Brit. Med. J. 4: 631-634 1973;
    CrossrefPubMedGoogle Scholar
  • 40 Bonnar J, McNichol G.P, Douglas A.S. Fibrinolytic enzyme system and pregnancy. Brit. Med. J. 3: 387-388 1969;
    CrossrefPubMedGoogle Scholar
  • 41 Ygge J. Changes in blood coagulation and fibrinolysis during the postoperative period. Amer. J. Surg. 779: 225-229 1970;
    PubMedGoogle Scholar
  • 42 Rennte J.A.N, Ogston D. Fibrinolytic activity in malignant disease. J. Clin. Path. 28: 872-877 1975;
    CrossrefPubMedGoogle Scholar
  • 43 Almer L.O, Janzon L. Low vascular fibrinolytic activity in obesity. Thromb. Res. 6: 171-172 1975;
    CrossrefPubMedGoogle Scholar
  • 44 Edward N, Young D.P.G, MacLeod M. Fibrinolytic activity in plasma and urine in chronic renal disease. J. Clin. Path. 17: 365-368 1961;
    PubMedGoogle Scholar
  • 45 Taylor F.B, Nilsson V.R, Crrech R.H. et al. Coagulolysis mechanism of formation and lysis of whole dilute blood clots and application of the assay into the study of certain hypercoagulable states. Seminars in Hemotology 6: 528-541 1973;
    PubMedGoogle Scholar
  • 46 Behnke O. Electron microscopical observations on the surface coating of human blood platelets. J. Ultrastruct. Res. 24: 51-69 1968;
    CrossrefPubMedGoogle Scholar
  • 47 Holme R, Sixma J.J, Murer E.H. et al. Demonstration of platelet fibrinogen secretion via the surface connecting system. Thromb. Res. 3: 347-356 1973;
    CrossrefPubMedGoogle Scholar
  • 48 Nichols W.L, Gerrard J.M, Didisheim R. Platelet structure, biochemistry and physiology. In: Poller L. (ed.) Recent Advances in Blood Coagulation-3. Churchill Livingstone; Edinburgh: 1981: 1-39.
    Google Scholar
  • 49 Holmsen H, Weiss H.J. Secretable storage pools in platelets. Ann. Rev Med. 30: 119-134 1979;
    CrossrefPubMedGoogle Scholar
  • 50 Niewiarowski S. Proteins secreted by the platelets.- Thromb. Haemost. 38: 924-938 1977;
    Article in Thieme ConnectPubMedGoogle Scholar
  • 51 Haslam R.J. Role of adenosine diphosphate in the aggregation of human blood-platelets by thrombin and by fatty acids. Nature 202: 765-768 1964;
    CrossrefPubMedGoogle Scholar
  • 52 Brodie G.N, Baenziger N.L, Chase L.R. et al. The effects of thrombin on adenyl cyclase activity and a membrane protein from human platelets. J. Clin. Invest. 57: 81-88 1972;
    PubMedGoogle Scholar
  • 53 Berridge M.J. The interaction of cyclic nucleotides and calcium in the control of cellular activity. Adv. Cyclic Nucleotide Res. 6: 1-98 1975;
    PubMedGoogle Scholar
  • 54 Bowie E.J.W, Owen C.A. The hemostatic mechanism, Chap. 2. In: Kwaan H.C, Bowie E.J.W. (eds.) Thrombosis. Saunders; Philadelphia: 1982: 7-22.
    Google Scholar
  • 55 Smith J.B, Willis A.L. Formation and release of prostaglandin by platelets in response to thrombin. Brit. J. Pharmacol. 50: 545P-546P 1970;
    PubMedGoogle Scholar
  • 56 O’Brien J.R, Tulevski V.G, Etherington M. et al. Platelet function studies before and after operation and the effect of postoperative thrombosis. J. Lab. Clin. Med. 81: 342-346 1974;
    PubMedGoogle Scholar
  • 57 O’Brien J.R, Etherington M.D, Jamieson S. et al. Blood changes in atherosclerosis and long after myocardial infarction and venous thrombosis. Thromb. Diath. Haemorrh. 34: 483-487 1975;
    PubMedGoogle Scholar
  • 58 Ludlam C.A, Moore S, Bolton A.E. et al. New rapid method for diagnosis of deep venous thrombosis. Lancet II: 259-260 1975;
    PubMedGoogle Scholar
  • 59 Schulz W, Brockhaus G, Konig R, Gessler U. Gerinnungsstörungen beim nephrotischen Syndrom. In: Schulz W, Gessler U. (Hrsg.) Gerinnungsstörungen und Anämie bei Nierenerkrankungen. Dustri; München: 1975. S. 60-70.
    Google Scholar
  • 60 Bang N, Tygstad C, Schroeder J, Heidenreich R, Csisko C. Enhanced platelet function in glomerular renal disease. J. Lab. Clin. Med. 81: 651-660 1973;
    PubMedGoogle Scholar
  • 61 Walter E, Deppermann D, Andrassy K, Koderisch J. Platelet hyperaggregability as a consequence of the nephrotic syndrome. Thromb. Res. 23: 473-479 1981;
    CrossrefPubMedGoogle Scholar
  • 62 Remuzzi G, Marchesi D, Mecca G. et al. Platelet hypersensitivity in the nephrotic syndrome. Proc. EDTA 16: 487-494 1979;
    PubMedGoogle Scholar
  • 63 Carvalho A, Colman R, Lees R. Platelet function in hyperlipoproteinemia. New Engl. J. Med. 290: 434-438 1974;
    CrossrefPubMedGoogle Scholar
  • 64 Shattil S, Anaya-Galindo R, Bennett J, Colman R, Cooper R. Platelet hypersensitivity induced by cholesterol incorporation. J. Clin. Invest. 55: 636-643 1975;
    CrossrefPubMedGoogle Scholar
  • 65 Yoshida A, Aoki N. Release of arachidonic acid from human platelets. A key role for the potentiation of platelet aggregability in normal subjects as well as in those with nephrotic syndrome. Blood 52: 969-977 1978;
    PubMedGoogle Scholar
  • 66 Jorgensen K, Stoffersen E. On the inhibitory effect of albumin on platelet aggregation. Thromb. Res. 17: 13-18 1980;
    CrossrefPubMedGoogle Scholar
  • 67 Remuzzi G, Mecca G, Marchesi D, Livio M, de Gaetano G, Donati M, Silver M. Platelet hyperaggregability and the nephrotic syndrome. Thromb. Res. 16: 345-354 1979;
    CrossrefPubMedGoogle Scholar
  • 68 Sinha A, Shattil S, Colman R. Cyclic AMP metabolism in cholesterol-rich platelets. J. Biol. Chem. 252: 3310-3314 1977;
    PubMedGoogle Scholar
  • 69 Kreusser W, Andrassy K, Wietasch A. Gestörte Thrombozytenfunktion beim nephrotischen Syndrom. Verh. Dtsch. Ges. Inn. Med. 87: 704-707 1981;
    PubMedGoogle Scholar
  • 70 Adler A.J, Lundin A.P, Feinroth A.P. et al. B-thromboglobulin levels in the nephrotic syndrome. Amer. J. Med. 69: 551-554 1980;
    CrossrefPubMedGoogle Scholar
  • 71 Andrassy K, Deppermann D, Walter E, Koderisch J, Ritz E, Post P. Is beta thromboglobulin a useful indicator of thrombosis in nephrotic syndrome?. Thromb. Haemost. 42: 486 1979;
    PubMedGoogle Scholar